XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
  Parkinson's
  Dementia
   Alzheimer's
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
 
 India
Search

Last Updated: Nov 18, 2006 - 12:32:53 PM
Research Article

Alzheimer's Channel
subscribe to Alzheimer's newsletter

Latest Research : Aging : Dementia : Alzheimer's

   DISCUSS   |   EMAIL   |   PRINT
Cathepsin B - Part of protective mechanism against Alzheimer's
Sep 21, 2006 - 12:02:00 AM, Reviewed by: Dr. Sanjukta Acharya

Gan and colleagues concluded that "our findings suggest that inhibition or loss of CatB function could interfere with its protective function and promote the development of AD, whereas overexpression of CatB could counteract A� accumulation and aggregation. Thus, pharmacological activation of CatB could downregulate A�1-42 assemblies through C-terminal truncation, offering an approach to the treatment of AD."

 
An enzyme found naturally in the brain snips apart the protein that forms the sludge called amyloid plaque that is one of the hallmarks of Alzheimer's disease (AD), researchers have found. They said their findings in mice suggest that the protein, called Cathepsin B (CatB), is a key part of a protective mechanism that may fail in some forms of AD. Also, they said their findings suggest that drugs to enhance CatB activity could break down amyloid deposits, counteracting one of the central pathologies of AD.

Li Gan and colleagues published their findings in the September 21, 2006, issue of the journal Neuron, published by Cell Press.

Their experiments were prompted by previous studies showing that the cysteine protease CatB--an enzyme that snips apart proteins--closely associated with the amyloid-� (A�) protein that forms the amyloid plaques, a hallmark of AD. However, those studies had not determined whether CatB was "good" or "bad"--that is, whether it acted to produce A� from a longer protein, called amyloid precursor protein (APP), or whether it broke down A�.

In their experiments, Gan and colleagues determined that CatB was the latter--breaking down A�, apparently to enable other enzymes to further degrade the protein for the cell's protein "garbage deposal" system.

They found that knocking out the CatB gene increased plaque deposition in a mouse model of AD in which mice expressed the human form of APP. They also found that CatB tended to accumulate within amyloid plaques and that it acted to reduce A� levels in neurons. And they found that introducing a pathological form of A�, called A�1-42, into neurons increased CatB in young and middle-aged mice with human APP, but not old mice. "Thus, upregulation of CatB may represent a protective mechanism that fails with aging," wrote the researchers, and such failure may play a role in late-onset sporadic AD.

Their test tube studies showed that CatB biochemically degrades A� by snipping one end of the protein, called the C-terminal end. What's more, the enzyme also degrades the long strings of A� that form amyloid plaque, they found.

Finally, they found that increasing levels of CatB in aging mice with human APP markedly reduced plaque deposits in the animals' brains.

Gan and colleagues concluded that "our findings suggest that inhibition or loss of CatB function could interfere with its protective function and promote the development of AD, whereas overexpression of CatB could counteract A� accumulation and aggregation. Thus, pharmacological activation of CatB could downregulate A�1-42 assemblies through C-terminal truncation, offering an approach to the treatment of AD."

 

- Cell Press
 

 
Subscribe to Alzheimer's Newsletter
E-mail Address:

 

The researchers include Sarah Mueller-Steiner, Yungui Zhou, Erik D. Roberson, Binggui Sun, Jennifer Chen, Xin Wang, Guiqiu Yu, Luke Esposito, Lennart Mucke, and Li Gan of University of California, San Francisco in San Francisco, California; Hideaki Arai of University of California, San Francisco in San Francisco, California and University of Tokyo in Tokyo, Japan.

This work was supported in part by NIH grants (to L.G. and L.M.) and a pilot project grant from the UCSF Alzheimer's Disease Research Center (to L.G.). S.M.-S. was supported by a fellowship from the Swiss Science Foundation. H.A. was supported by an Overseas Advanced Educational Research Practice Support Program grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan. L.M. has a consulting relationship with Merck and has received honoraria or fees for lectures from Amgen, Elan, and Pfizer. These companies did not, however, provide financial or scientific support for the present study.

Mueller-Steiner et al.: "Antiamyloidogenic and Neuroprotective Functions of Cathepsin B: Implications for Alzheimer's Disease." Publishing in Neuron 51, 703�714, September 21, 2006.


Related Alzheimer's News

Hope remains for Alzheimer's sufferers
CATIE Study: Antipsychotics in Alzheimer's No Better Than Placebo
Mediterranean diet associated with a lower risk for Alzheimer�s disease
Omega-3 fatty acid supplements may slow cognitive decline
Microscopic brain damage detected in early Alzheimer's disease
Novel technique can identify early cellular damage in Alzheimer's disease
Cathepsin B - Part of protective mechanism against Alzheimer's
Boosting ubiquitin C-terminal hydrolase L1 (Uch-L1) restores lost memory
New research points toward mechanism of age-onset toxicity of Alzheimer's protein
Structure of calbindin-D28K Protein Involved in Preventing Alzheimer�s, Huntington�s Diseases Characterised


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us